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INTRODUCTION Liver fibrosis is caused by an imbalanced remodeling process due to chronic inflammation associated with excessive scar tissue formation (Seki and Schwabe, 2015) . Hepatic stellate cells (HSC), key players in this process, transform from quiescent cells into proliferative, fibrogenic and contractile myofibroblast-like cells in response to growth factors such as transforming growth factor β (TGFβ) and platelet derived growth factor BB (PDGF-BB) (Seki and Schwabe, 2015) . The differentiation and activation of HSC is tightly controlled by the activity of cAMP (Mallat et al., 1998) . Increased intracellular cAMP levels inhibit fibroblast migration and proliferation and block the phenotype switch into myofibroblasts, leading to less scar tissue formation (Swaney et al., 2005) .
Protein Kinase A (PKA) is a well-known second messenger system that mediates the effects of cAMP.
More recently, Exchange Protein Activated by cAMP (Epac) was identified as an important signaling mechanism for cAMP-mediated effects (Insel et al., 2012; Lezoualc'h et al., 2016; Schmidt et al., 2013) . Epac is involved in the regulation of key cellular processes, such as calcium handling, neural signaling, inflammation, proliferation and migration by promoting the exchange of GTP and GDP in the GTPase cycle (Schmidt et al., 2013; Yang et al., 2015; Yu et al., 2016) . Two isoforms of Epac have been identified: Epac-1, found in heart, vasculature, brain, kidney and lungs, and Epac-2, mostly found in brains and adrenal glands. Of interest, Epac-1 is reported to be involved in fibrogenesis. In several reports significant lower Epac-1 expressions were observed during activation of myofibroblasts (Insel et al., 2012; Schmidt et al., 2013; Yokoyama et al., 2008) . However to date, nothing is known about mechanisms or factors that can enhance Epac-1 expression and the consequences of this enhancement for fibrogenic processes in vivo (Insel et al., 2012) .
The cyclooxygenase (COX) product prostaglandin E 2 (PGE 2 ) affects cAMP levels directly in most cell types. In fibroblasts, PGE 2 exerts anti-fibrotic activities through cAMP activation by binding to EP2 or EP4 receptors (Mallat et al., 1998; Ruwart et al., 1989; Weinberg et al., 2009) . We therefore investigated the effects of PGE 2 and the COX-inhibitor niflumic acid (NFA) on Epac-1 expression levels in the CCl 4 -induced mouse model for liver fibrosis. In addition, we used a cell-specific delivery approach to deliver PGE 2 to several resident hepatic cells to identify its most important target cell in vivo. Our studies show a decreased Epac-1 protein expression in fibrotic livers relative to normal JPET #241646 8 18hr, 3 H-thymidin (0.25 µCi/ml) was added for 6 hr. Cells were washed, fixed with 5% TCA, lysed with 1M NaOH, and radioactivity was counted.
Migration Assay: Primary rat HSC (6x10 4 cells/well) were cultured in Transwell chambers (8 µm pore size; Costar) with PGE 2 or agonists. PDGF-BB was added to the lower chamber. After 24hr, membranes were fixed and stained with hematoxylin. Cells on both sides of the membrane were counted in at least five fields/membrane (magnification 40x). Migration was calculated as percentage of cells in the lower chamber relative to total cell number.
In vitro effects of PGE 2 -conjugates: HepG2 cells (150.000 cells/well) were incubated with PGE 2 and equimolar amounts of PLH for 60 min. Cells were processed and used for Western Blot analysis using VASP-1 antibody. RAW264.7 cells were incubated with 100 ng/ml LPS plus 10 µM PGE 2 , equimolar amounts of PMH, or vehicle. After 24 hr, medium was harvested and total NO production was assessed (Melgert et al., 2001) . LX2 cells were grown to confluency in 12-wells plates. A standard scratch was made after which cells were incubated for 24hr with 10 ng/ml PDGF-BB plus 5 µM PGE 2 , equimolar amounts of PPH, or vehicle. The scratch size was measured using imaging techniques at t=0 hr and t=24 hr yielding the % wound healing.
Epac-1 and PKA expression: 3T3 fibroblasts (100.000 cells/well) were incubated with PGE 2 (0.1, 1, 5, 10 µM) for 6, 24 and 48 hr. Cells were homogenized and processed for Western Blot and PCR analysis.
Rap1 expression: 3T3 cells (25.000 cells/well), seeded in glass labteks, were incubated with 10 µM PGE 2 and 20 µM Epac-1 antagonist CE3F4 (Courilleau et al., 2012) for 60 min. After fixation in acetone/methanol (1:1), Rap1 was stained (O/N,4ºC) using the primary antibody (Santa Cruz), and subsequently visualized using Alexa488-goat anti rabbit IgG (Invitrogen) and DAPI.
Animal Experiments
All animal experiments were approved by the Animal Ethics Committee of the University of Groningen, the Netherlands.
CCl 4 Model: Male Balb/c mice (20-22g, Harlan, Zeist, Netherlands) received CCl 4 for 8 weeks, according to standard protocols (Beljaars et al., 2003) . At week 7 and 8, mice also received (iv, 3 This article has not been copyedited and formatted. The final version may differ from this version.
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JPET #241646 9 times/week) 0.5 mg/kg PGE 2 , 5 mg/kg NFA, vehicle (PBS), PPH, PH, PMH, MH, PLH, or LH (n = 6-9/ group). All animals received the same PGE 2 dose either free or bound to the albumin drug carrier.
Mice were sacrificed at week 8. Two animals from each group received i.v. a PGE 2 -loaded carrier 15 min prior to sacrifice to check whether the PGE 2 -carrier conjugate still accumulated in the designated target cell. The liver enzymes alanine transaminase (ALT) and aspartate transaminase (AST), reflecting liver damage, were measured in plasma according to routine methods at the clinical chemistry lab of the University Medical Center Groningen, the Netherlands.
Human tissue
Human liver tissue samples were obtained from the Department of Surgery and Liver Transplantation (University Medical Center Groningen, the Netherlands). All patients signed an informed consent for the use of residual tissue for research purposes. Experimental protocols were approved by the Medical Ethical Committee and anonymized tissue samples were used according to Dutch guidelines (http://www.federa.org/gedragscodes-codes-conduct-en). Normal human liver tissue was obtained from donor livers discarded for transplantation for technical reasons. Cirrhotic human liver tissue was obtained from patients undergoing liver transplantation and indications for transplantation were a.o. primary sclerosing cholangitis, primary biliary cirrhosis, congenital cirrhosis, alcohol-induced liver disease, acute liver failure and Wilson's cirrhosis. All human liver material was anonymized and available patient characteristics are listed in Table 1 .
Tissue analysis
Immunohistochemistry. Cells and cryostat sections were stained according to standard methods. PGE 2 ELISA: Liver samples were homogenized and PGE 2 amounts were assessed using the monoclonal PGE 2 EIA kit (Cayman Chemicals) according to manufacturer's instructions.
Statistical Analysis
Results are expressed as mean ± SEM. Statistical analyses were performed using the Mann Whitneytest and considered significant at p < 0.05. 
RESULTS

PGE 2 and NFA affect liver fibrosis in CCL 4 -treated mice
Mice received CCl 4 for 8 weeks to induce liver fibrosis. During the last 2 weeks of CCl 4 administration, the mice were treated with PGE 2 (n=9), the COX-2 inhibitor NFA (n=6) or vehicle (PBS; n=9). Normal mice, receiving only PBS, served as control (n=9). Plasma levels for alanine transaminase (ALT) and aspartate transaminase (AST) indicated significant liver damage in all CCl 4treated mice (see table 2 ). No major differences in damage were seen between fibrotic animals receiving different compounds in the final two weeks, although a reduced average in plasma ALT level was seen in NFA-treated animals (p<0.05). Markers reflecting HSC activation (αSMA) and matrix deposition (collagen I) were examined both at the mRNA (Supplemental Figure 1 ) and protein level (Fig 1) . Immunohistochemistry and rtPCR analysis showed that PGE 2 -treated mice displayed significantly less intrahepatic αSMA and collagen I expression levels compared to CCl 4 -mice receiving no treatment ( fig. 1A-D) . In contrast, NFA induced a significant increase in αSMA and collagen I protein levels in fibrotic mice compared to CCL 4 -mice receiving no treatment. pSMAD2/3 expression levels, indicating TGFβ signaling, were strongly enhanced in CCL 4 -receiving mice treated with PBS ( Fig 1E) . Treatment with PGE 2 significantly reduced these levels, whereas NFA administration enhanced pSMAD2/3 levels in fibrotic animals.
Measurement of intrahepatic PGE 2 levels revealed that CCL 4 -mice displayed increased intrahepatic PGE 2 levels relative to healthy animals (p< 0.01, fig. 1F ). PGE 2 treatment significantly reduced these levels compared to untreated fibrotic mice (p<0.01). NFA treatment completely abolished intrahepatic PGE 2 production in fibrotic animals.
PGE 2 enhances Epac-1 expression and attenuates Rho-activity in vivo
Previous in vitro studies showed that PGE 2 activates cAMP in myofibroblasts (Huang et al., 2008) .
We now examined intrahepatic expression levels of both cAMP mediators PKA and Epac-1 in CCL 4treated mice. In fibrotic livers a significant reduction in Epac-1 protein expression levels was observed relative to healthy mice livers (fig 2A) , in agreement with previous reports (Insel et al., 2012; Schmidt et al., 2013; Yokoyama et al., 2008) . PGE 2 -treatment completely restored Epac-1 levels in fibrotic livers. In contrast, NFA-treatment further reduced Epac-1 levels in fibrotic animals. Western blot This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. analysis did not reveal significant changes in PKA expression levels in CCl 4 -treated animals as compared to normal mice and expression levels for PKA were also not affected by PGE 2 or NFA treatment.
We also examined human livers for Epac-1 expression. Western blots revealed that Epac-1 expression levels were significantly reduced also in human fibrotic livers, irrespective of etiology, compared to control livers ( fig. 2C ).
Rho-kinase is reported to be a downstream target of Epac-1 (Roscioni et al., 2011; Schmidt et al., 2013) . Rho-kinase in turn stimulates fibroblast-to-myofibroblast transdifferentation, migration and contraction of these cells via phosphorylation of the Myosin Light Chain (i.e. formation of PMLC) (Mack et al., 2001) . This PMLC stimulates Myosin II ATP-ase activity and contraction of actin fibers in HSC, leading to portal hypertension, one of the hallmarks of fibrosis (Klein et al., 2012) . Recently, reports showed that Epac-1 inhibits phosphorylation of MLC. In fibrotic mice, clear staining for PMLC in the fibrotic bands was visible, while little or no expression was seen in healthy animals ( Fig   2D) . PMLC staining co-localized with desmin staining, the marker for HSC. Fibrotic animals treated with PGE 2 displayed no PMLC staining in fibrotic bands or in any desmin positive cell at all.
Collectively, our data show that PGE 2 attenuated αSMA and Collagen I expression in fibrotic mice which is associated with an increase in Epac-1 levels and inhibition of its downstream target Rhokinase compared to untreated fibrotic mice. In contrast, NFA increased HSC activation and collagen deposition and further reduced Epac-1 expression in fibrotic animals.
Cell-specific delivery of PGE 2 to resident hepatic cells.
Epac-1 proteins are expressed in many resident and circulating cells. We therefore used a drug targeting approachto assess which cell-type is involved in the observed effects on intrahepatic Epac-1 levels and fibrogenesis. We therefore coupled PGE 2 to cell-specific carriers directed at either HSC, Kupffer cells or hepatocytes ( fig. 3A ). Lactosylated human serum albumin (LH) which binds to the asialoglycoprotein receptor is a well-known carrier to hepatocytes (Beljaars et al., 1998) . PDGFβreceptors and mannose-receptors are highly expressed on respectively activated HSC (Seki and Schwabe, 2015) and macrophages (Beljaars et al., 1998; Melgert et al., 2001) , which both are abundantly present in fibrotic livers. These receptors are suitable targets for respectively HSC-and KC delivery. Therefore, we coupled PDGFβ-receptor recognizing peptides to HSA (pPB-HSA) to obtain a HSC-selective carrier and attached mannose to HSA (MH) to reach macrophages. The cellspecificity of all these carriers has been described in vivo in earlier reports (Beljaars et al., 1998; Beljaars et al., 2003; Melgert et al., 2001) . PGE 2 was subsequently coupled to each carrier. Cellspecificity of carriers was retained after attachment of PGE 2 : PGE 2 attached to pPB-HSA (=PPH) was found in Desmin positive-cells, reflecting HSC, 15 min after its administration to fibrotic mice. Subsequently, we studied Epac-1 and PKA expression levels in mice treated with PGE 2 -conjugates or their respective control compounds. Only in livers of PPH-treated mice we found significant upregulation of Epac-1 expression compared to PBS-treated fibrotic mice ( fig. 3E ). All other treatments didn't induce any alteration in Epac-1 expression. PKA expression was not different from untreated fibrotic mice in any of the groups (fig. 3E ). The increase in Epac-1 expression in mice treated with the HSC-selective PGE 2 conjugate was, similar to PGE 2 alone (see also fig 2E) , associated with a significant reduction in PMLC expression in HSC (desmin-positive cells) in fibrotic livers ( fig.   4 ). Other treatments (i.e PLH and PMH) and controls did not induce a change in hepatic pMLC Collectively, these drug targeting studies show that hepatic stellate cells, rather than Kupffer cells, hepatocytes or circulating immune cells are the effector cells of PGE 2 -induced changes in hepatic
Epac-1 levels. These data also confirm the association between Epac-1 and Rho-kinase activity in HSC in vivo.
PGE 2 induces Rap1 translocation in vitro
To test whether PGE 2 is able to directly activate Epac-1 in fibroblasts we added PGE 2 to 3T3 cells and examined Epac-1 expression at the mRNA and protein level as well as Epac-1 activation. No change in Epac-1 levels at mRNA nor protein levels was found (data not shown). However, a change in Rap1 staining was noted ( fig 5) . Epac-1 is known to induce translocation of Rap1 from the cytosol to plasma membranes (Yang et al., 2015) . Figure 5 shows Rap1 staining evolving from a general weak cytoplasmatic staining within fibroblasts to a more concentrated intense staining along membranes after addition of PGE 2 indicating re-localization and concentration of Rap1. In turn, the PGE 2 -induced relocalisation was inhibited by the Epac-1 inhibitor CE3F4 (Courilleau et al., 2012) . This indicates the involvement of Epac-1 in this PGE 2 -mediated effect.
Effects of Epac-1 and PKA agonists in primary HSC
Our in vivo data implicate that fibrogenic mediators reduce Epac-1 expression whereas Epac-1 enhancement leads to inhibition of HSC activities. We tested this in vitro using primary HSC, isolated from rats. In these primary cells, PDGF-BB and TGFβ significantly reduced Epac-1 mRNA expression levels compared to unstimulated cells, whereas no changes in PKA mRNA levels were seen ( fig. 6A ). Subsequently, the PKA agonist 6-Bnz-cAMP and the Epac-1 agonist 8-pCPT-2'-O-Me-cAMP (Roscioni et al., 2009; Roscioni et al., 2011) were used to study the effects of the Epac-1 and PKA signaling pathway on PDGF-induced migration and proliferation in rHSC. Both agonists attenuated PDGF-induced migration of rHSC ( fig 6B) . The Epac-1 agonist also inhibited PDGFinduced proliferation in rHSC, whereas the PKA-agonist had no effect ( fig. 6B ). 
DISCUSSION
This study demonstrates the involvement of the cAMP effector Epac-1 in the regulation of hepatic fibrogenesis in vitro and in vivo. Epac proteins, alone or in concert with PKA, are closely involved in the regulation of pivotal processes including cell survival, proliferation and differentiation, immune responses, and signaling cascades (Lezoualc'h et al., 2016; Roscioni et al., 2011; Yokoyama et al., 2008) . Despite these activities, little is known about Epac during liver fibrosis in vivo. The relevance of Epac-1 during fibrogenesis has been inferred from studies showing a reduced Epac-1 expression after fibroblast activation in several organs (Insel et al., 2012; Lezoualc'h et al., 2016; Roscioni et al., 2011; Schmidt et al., 2013) . It was therefore suggested that upregulation of Epac-1 might attenuate fibrosis (Insel et al., 2012; Schmidt et al., 2013) . However, methods to achieve such an upregulation were unknown (Insel et al., 2012) . Our in vivo experiments in fibrotic mice now show that Epac-1 can be upregulated in HSC by PGE 2 . This is associated with reduced fibrogenesis in vivo.
PGE 2 was found to exert significant antifibrotic effects in mice with liver fibrosis, as reflected in this study by reduced collagen I, αSMA and pSMAD2/3 levels. The COX-2 inhibitor NFA induced the opposite effects on these parameters. This profibrotic effect cannot be explained by increased damage induced by NFA (see table 2 ). Also others found a profibrotic effect of COX-2 inhibitors (Gilroy et al., 1999) but the mechanism behind this always has been unclear. Our studies suggest a role for Epac-1 in this cascade of cyclooxygenase-induced effects.
PGE 2 signals through intracellular cAMP inducing PKA or Epac-1 activation. Whereas PKA levels did not change in our studies, Epac-1 dropped significantly during hepatic fibrogenesis in mice and after HSC activation in vitro, confirming earlier reports (Insel et al., 2012) . A limited survey in human tissue samples indicates that this reduction also occurs in patients with different liver diseases. PGE 2 and NFA displayed opposite effects in fibrotic livers: a strong up-regulation of Epac-1 was seen after PGE 2 treatment, and a down-regulation after NFA treatment. NFA treatment was shown to abolish intrahepatic PGE 2 production, confirming effective inhibition. These observations suggest that the anti-fibrotic effects of PGE 2 are, at least partly, mediated by Epac-1.
Our data seemingly reveal a contradiction. We showed that PGE 2 administration enhanced Epac-1 expression in fibrotic livers, yet liver fibrosis is associated with high hepatic PGE 2 levels ( fig 1F) and reduced Epac-1 expression ( fig 2C) . Moreover, PGE 2 -treatment attenuated intrahepatic PGE 2 production, yet enhanced Epac-1 levels. It is clear that total intrahepatic PGE 2 content does not correlate with Epac-1 or fibrosis. Of note, the plasma t½ of the administered PGE 2 (5 min) is too short to be detectable at the time of sacrifice (24 hr after injection). PGE 2 and NFA are both antiinflammatory compounds and consequently can both attenuate PGE 2 production by inflammatory cells (Gilroy et al., 1999) . At the same time they have opposite effects on fibrogenesis, HSC activation and Epac-1 levels (see fig 1 and 2A) . Cell-specific delivery of PGE 2 to HSC did enhance intrahepatic
Epac-1 levels and attenuated fibrogenesis and HSC activation. Therefore, it can be deduced that PGE 2 affects fibrosis via an effect on Epac-1 levels specifically within HSC, irrespective of the total PGE 2 content within livers.
One of the downstream targets of Epac-1 is Rho-kinase (Yu et al., 2016) , which was found to be downregulated by Epac-1 (Rajagopal et al., 2013; Roscioni et al., 2011; Schmidt et al., 2013) . Rhokinase stimulates the transdifferentiation of HSC into collagen-producing myofibroblast-like cells via phosphorylation of its downstream substrate, myosin light chain (MLC) (Mack et al., 2001) . This prompted us to examine PMLC levels in fibrotic livers. Indeed, PMLC was abundantly expressed in desmin-positive cells in fibrotic septa in livers of untreated mice. In contrast, in fibrotic mice treated with PGE 2 , PMLC formation was completely absent, indicating a lower Rho-kinase activity at these sites. Rho-kinase has profound effects on portal pressure via actin-filament contraction in HSC (Klein et al., 2012) and portal hypertension is a key factor in clinical complications during cirrhosis, so the modulation of Rho-kinase activity by PGE 2 in HSC is quite relevant.
PGE 2 is pleiotropic molecule affecting many cell types including (circulating) inflammatory cells, smooth muscle cells, hepatocytes, and macrophages (Haag et al., 2008; Hui et al., 2004) . To investigate which cell type was responsible for the observed alterations we used different albuminbased cell-selective carriers. Cell-selectivity of the applied carriers has been extensively demonstrated in previous studies (Beljaars et al., 1998; Beljaars et al., 2003) . Cell specificity was verified for all PGE 2 constructs: all constructs were taken up by the designated target cells as illustrated by double staining for albumin and specific cell markers. Also pharmacological activity of constructs was verified in cell lines expressing the designated target receptor (i.e. the PDGFβ-R, Mannose-R, or the asialoglycoprotein-R) and we started therapies in a late stage of disease, when target receptor expression is high. In vivo, only HSC-selective PGE 2 delivery inhibited the CCl 4 -induced scar tissue formation, normalized Epac-1 expression levels and abolished PMLC protein expression, thereby excluding a role for KC, hepatocytes and circulating or infiltrating inflammatory cells. We did not test the effect of PGE 2 on sinusoidal endothelial cells yet. Studies with PGE 2 coupled to endothelialspecific carriers need to be performed in order to exclude a role for this cell type. Our approach however led to insight in a very complex situation, where inflammation and fibrosis interact and PGE 2 exerts many effects in multiple cell types. Collectively, our cell-selective approach shows that PGE 2 increases Epac-1 within HSC, which is associated with local inhibition of Rho-kinase activity and reduced fibrogenesis in CCl 4 -treated mice.
In vitro studies confirmed Epac-1-mediated effects by PGE 2 on fibroblasts: Rap1 translocation to the plasma membrane, reported to be induced by Epac-1 (Yang et al., 2015) , was seen after addition of PGE 2 to fibroblast and this was inhibitable by the Epac-1 inhibitor CE3F4 (Courilleau et al., 2012) .
Although PGE 2 is known for its role in inflammation and fibrosis (Haag et al., 2008; Huang et al., 2008; Mallat et al., 1998; Weinberg et al., 2009) , literature on the effects of PGE 2 on liver fibrosis in vivo is scarce. One study (Ruwart et al., 1989 ) demonstrated reduced collagen deposition in cirrhotic rats treated with PGE 2 , although the mechanism of action behind this was unknown. This lack of clarity is most likely due to the pleiotropic effects of PGE 2 and its poor pharmacokinetic profile; it is rapidly cleared by the liver and kidneys, or inactivated by plasma proteins. In fact, it's surprising that despite its short half-life, significant effects of PGE 2 were found on liver fibrosis. Similar to PGE 2 , the effect of COX-activity on fibrogenesis in vivo is unclear. COX-inhibitors are reported to be either pro- (Gilroy et al., 1999) or anti-fibrotic (Chavez et al., 2010) which may indicate a dual effect on fibrogenesis; their anti-inflammatory effects may lead to anti-fibrogenic effects, whereas effects on fibrogenic cells, for instance via inhibition of PGE 2 production, may stimulate fibrogenesis. This remains to be elucidated but the present study provides clues for such a dual effect of PGE 2 and COXinhibitors.
In summary, our study shows the involvement of the cAMP effector Epac-1 in the regulation of liver fibrosis. Fibrogenesis is associated with a reduced Epac-1 expression in vivo. Restoration of Epac-1 Figure A. schematically outlines the different constructs and target cells. Figure B . 
